BioMerieuxLTS:0RUG +2.10%71 Operating Margin % is 16.75% as of Dec. 2025, which is 6% above its 10-year median of 15.76. GuruFocus rates LTS:0RUG with a GF Score™ of 71/100 and a GF Value™ of €109.89 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, BioMerieux ranks better than 83.33% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. BioMerieux's Operating Income for the
six
months ended in Dec. 2025 was €339 Mil. BioMerieux's Revenue for the
six
months ended in Dec. 2025 was €2,026 Mil. Therefore, BioMerieux's Operating Margin % for the quarter that ended in Dec. 2025 was 16.75%.
Warning Sign:
BioMerieux SA operating margin has been in a 5-year decline. The average rate of decline per year is -6%.
The historical rank and industry rank for BioMerieux's Operating Margin % or its related term are showing as below:
LTS:0RUG'
s Operating Margin % Range Over the Past 10 Years
Min: 13.85 Med: 15.76 Max: 25
Current: 17.07
LTS:0RUG's Operating Margin % is ranked better than 83.33% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.195
vs LTS:0RUG: 17.07
BioMerieux's 5-Year Average Operating Margin % Growth Rate was -6.00% per year.
BioMerieux's Operating Income for the
six
months ended in Dec. 2025 was €339 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €695 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
BioMerieux Operating Margin % Related Terms
BioMerieux Operating Margin % Historical Data
* Premium members only.
The historical data trend for BioMerieux's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RUG vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, BioMerieux's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMerieux Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's Operating Margin % distribution charts can be found below:
* The bar in red indicates where BioMerieux's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
BioMerieux's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMerieux (LTS:0RUG) has a Operating Margin % of 16.75% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on BioMerieux and its competitors. This is near median its historical median of 15.76. Over the past decade, BioMerieux's Operating Margin % has ranged from 13.85 to 25.00. According to the industry distribution chart, BioMerieux ranks #34 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is BioMerieux's Operating Margin % too high?
BioMerieux's current Operating Margin % of 16.75% is near median its 10-year median of 15.76. Over the past 10 years, this metric has ranged from a low of 13.85 to a high of 25.00. Based on the distribution chart, BioMerieux ranks #34 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BioMerieux has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BioMerieux ranks #34 out of 204 companies for Operating Margin %. This places BioMerieux in the top 17% of its industry — outperforming the majority of peers. Historically, BioMerieux's own Operating Margin % has ranged from 13.85 to 25.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on BioMerieux and its competitors. BioMerieux's current Operating Margin % is 16.75%, which is near median its own 10-year median of 15.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (LTS:0RUG) is currently considered Significantly Undervalued. The stock's GF Value™ is €109.89, compared to a current price of €67.95 — trading 38.2% below its estimated fair value. The current Operating Margin % is 16.75%, which is near median its 10-year median of 15.76. BioMerieux's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For BioMerieux (LTS:0RUG), the current Operating Margin % is 16.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMerieux (LTS:0RUG) Overvalued in 2026?
Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued.
The current stock price of €67.95 is trading 38.2% below its estimated GF Value™ of €109.89.
GuruFocus considers BioMerieux to be Significantly Undervalued.
Key valuation signals for LTS:0RUG:
Operating Margin %: 16.75% (near median its 10-year median of 15.76)
GF Value™: €109.89 vs. price of €67.95 (38.2% below fair value)
No single metric tells the full story. See the LTS:0RUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
71GF Score
Get the complete analysis for LTS:0RUG
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RUG has been successfully added to your 
